Latest news

• AstraZeneca’s Evusheld not recommended by NICE for COVID-19 prevention

  Evusheld contains two antibodies that boost protection against COVID-19 for those who are unlikely to have an adequate immune response to vaccination, or who cannot be vaccinated. ... from vaccination against COVID-19 as most people, and who therefore

• RQ Bio-discovered antibody enters clinic as part of AstraZeneca COVID-19 study

  RQ Bio has announced that the first of its discovered monoclonal antibodies (mAbs) to prevent COVID-19 in vulnerable patients has entered clinical trials less than 12 months after discovery, with ... community of infectious disease antibody experts to

• Lack of evidence for AstraZeneca’s COVID-19 vaccine says UK Department of Health

  The UK’s Department of Health and Social Care has decided not to buy AstraZeneca’s COVID-19 drug, Evusheld, due to a lack of evidence about the vaccine’s effectiveness ... Developed by AstraZeneca, Evusheld is a combination of two antibodies that

• ONS data reveals significant decrease in COVID-19 antibodies

  New figures from the Office for National Statistics (ONS) show the percentage of the UK population estimated to have COVID-19 antibodies is declining rapidly, prompting calls for the government to ... antibodies to COVID-19 is obviously concerning.

• New Swiss research reveals how Omicron evades the immune system

  A team from the University of Geneva and the Geneva University Hospital analysed the antibody neutralisation capacity of 120 people previously infected with one of the different COVID-19 variants. ... Researchers from the University of Geneva (UNIGE) and